After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Deucrictibant is an orally administered bradykinin B2 ...

Ionis Pharmaceuticals (IONS) and its Japanese partner, Otsuka Pharmaceutical (OTSKY), said on Wednesday that the European ...

BioCryst adds navenibart, a late-stage, long-acting plasma kallikrein inhibitor currently in Phase 3 clinical development, to its HAE portfolio. The potential to be the first HAE therapy with ...

New York, USA, May 06, 2025 (GLOBE NEWSWIRE) -- Angioedema Clinical Trial Pipeline Analysis Demonstrates 15+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses ...

Ionis IONS and its Japanese partner, Otsuka Pharmaceutical, announced that the European Commission has approved Dawnzera (donidalorsen) for the prevention of recurrent attacks of hereditary angioedema ...

Hereditary angioedema (HAE) is a serious, potentially fatal disease of recurrent swelling of various subcutaneous and submucosal tissues throughout the body. Swelling is mediated by uncontrolled ...

Angioedema is a well-known side effect of treatment with an angiotensin-converting enzyme (ACE) inhibitor and one that we have been willing to accept in view of the incidence of the problem and the ...

Hereditary angioedema (HAE) is a rare genetic syndrome caused by a deficiency in functional C1 inhibitor that results in recurrent episodes of nonpruritic swelling of the hands, feet, arms, legs, ...

Angioedema is basically swelling of the deeper layers of the skin. This is due to accumulation of fluids caused by an allergic reaction. Pathogenesis of the types of angioedema has been studied ...

Please provide your email address to receive an email when new articles are posted on . Many patients with hereditary angioedema have poorly controlled disease ...